Moreover, the 36-month beta value for BNGO is 2.25. Analysts have varying opinions on the stock, with 5 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The average price recommended by analysts for Bionano Genomics Inc. (BNGO) is $4.06, which is $3.39 above the current market price. The public float for BNGO is 291.38M and currently, short sellers hold a 21.37% of that float. On May 25, 2023, BNGO’s average trading volume was 7.37M shares.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Sponsored
BNGO) stock’s latest price update
Bionano Genomics Inc. (NASDAQ: BNGO)’s stock price has plunge by -5.57relation to previous closing price of 0.71. Nevertheless, the company has seen a -4.77% plunge in its stock price over the last five trading sessions. The Wall Street Journal reported on 10/12/21 that Airbnb, Merck, High Tide, Square: What to Watch in the Stock Market Today
BNGO’s Market Performance
Bionano Genomics Inc. (BNGO) has seen a -4.77% fall in stock performance for the week, with a -9.36% decline in the past month and a -50.99% plunge in the past quarter. The volatility ratio for the week is 6.05%, and the volatility levels for the past 30 days are at 7.76% for BNGO. The simple moving average for the last 20 days is -3.80% for BNGO stock, with a simple moving average of -61.82% for the last 200 days.
BNGO Trading at -24.94% from the 50-Day Moving Average
After a stumble in the market that brought BNGO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -84.68% of loss for the given period.
Volatility was left at 7.76%, however, over the last 30 days, the volatility rate increased by 6.05%, as shares sank -7.84% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -46.24% lower at present.
During the last 5 trading sessions, BNGO fell by -4.77%, which changed the moving average for the period of 200-days by -73.86% in comparison to the 20-day moving average, which settled at $0.6901. In addition, Bionano Genomics Inc. saw -54.34% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BNGO starting from Holmlin R. Erik, who purchase 15,000 shares at the price of $0.64 back on May 16. After this action, Holmlin R. Erik now owns 806,474 shares of Bionano Genomics Inc., valued at $9,639 using the latest closing price.
Stewart Christopher P., the Chief Financial Officer of Bionano Genomics Inc., purchase 50,000 shares at $0.67 during a trade that took place back on May 12, which means that Stewart Christopher P. is holding 281,373 shares at $33,415 based on the most recent closing price.
Stock Fundamentals for BNGO
Current profitability levels for the company are sitting at:
- -466.09 for the present operating margin
- -9.55 for the gross margin
The net margin for Bionano Genomics Inc. stands at -476.93. The total capital return value is set at -42.56, while invested capital returns managed to touch -43.86. Equity return is now at value -53.40, with -44.90 for asset returns.
Based on Bionano Genomics Inc. (BNGO), the company’s capital structure generated 4.68 points at debt to equity in total, while total debt to capital is 4.47. Total debt to assets is 3.79, with long-term debt to equity ratio resting at 3.66. Finally, the long-term debt to capital ratio is 3.49.
When we switch over and look at the enterprise to sales, we see a ratio of 3.90, with the company’s debt to enterprise value settled at 0.04. The receivables turnover for the company is 4.34 and the total asset turnover is 0.08. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.38.
Conclusion
To wrap up, the performance of Bionano Genomics Inc. (BNGO) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.